137051-68-4
Chemical Structure
Chromozym t-PA
- CAS No.: 137051-68-4
- Formula:C24H32N8O7S
- Molecular Weight:576.63
InChIKey: JLSWTFADWDIADV-VQTJNVASSA-N
SMILES: CS(N[C@@H](C(NCC(N[C@H](C(NC1=CC=C([N+]([O-])=O)C=C1)=O)CCCNC(N)=N)=O)=O)CC2=CC=CC=C2)(=O)=O
Biological Activity: Chromozym t-PA is a chromogenic peptide substrate for factor VIIa and tPA. Chromozym t-PA is hydrolyzed by the serine protease factor VIIa, and its amidolytic activity is enhanced in the presence of tissue factor, releasing p-nitroaniline. Chromozym t-PA serves as a key biochemical reagent for evaluating and measuring the activity of tissue-type plasminogen activator (t-PA) and related proteases, and can be applied in biochemistry and clinical diagnostics[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Chromozym t-PA | 99.31% | Chromozym t-PA is a chromogenic peptide substrate for factor VIIa and tPA. Chromozym t-PA is hydrolyzed by the serine protease factor VIIa, and its amidolytic activity is enhanced in the presence of tissue factor, releasing p-nitroaniline. Chromozym t-PA serves as a key biochemical reagent for evaluating and measuring the activity of tissue-type plasminogen activator (t-PA) and related proteases, and can be applied in biochemistry and clinical diagnostics. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ghosh S, et al. Activity and regulation of glycoPEGylated factor VIIa analogs. Journal of thrombosis and haemostasis : JTH. 2008 Sep;6(9):1525-33.
- [2]. Neuenschwander PF, et al. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. Journal of Biological Chemistry. 1994 Mar 18;269(11):8007-13.
- [3]. Dennis MS, et al. Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa. Biochemistry. 2001 Aug 14;40(32):9513-21.
- [4]. Huang X, et al. A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood. 2006 Feb 01;107(3):980-6.
- [5]. Uesugi Y, et al. Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator. Journal of drug targeting. 2012 Apr;20(3):224-34.
- [6]. Johnsen LB, et al. A refined kinetic analysis of plasminogen activation by recombinant bovine tissue-type plasminogen activator indicates two interconvertible activator forms. Biochemistry. 1998 Sep 08;37(36):12631-9.
- [7]. Yang J, et al. Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa. Thrombosis and haemostasis. 2002 Mar;87(3):450-8.
- [8]. Peng ZC, et al. A novel anti-tissue factor monoclonal antibody with anticoagulant potency derived from synthesized multiple antigenic peptide through blocking FX combination with TF. Thrombosis research. 2007;121(1):85-93.
- [9]. Shobe J, et al. Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking. The Journal of biological chemistry. 1999 Aug 20;274(34):24171-5.
